



Vaccines for Children (VFC) Education Session

Respiratory Syncytial Virus (RSV) and COVID-19 Vaccines

September 26, 2024

Presenters

- Alex Thornton, VFC Lead.
- Antoinette Yuhas, Public Health Nurse Specialist.
- Theresa Bonn, Health Services Policy Analyst.

Immunization Program
Bureau of Infectious Diseases

Pre-Submitted Questions

A RedCap link was shared to collect questions for this education session.

We will respond to pre-submitted questions at the end of the session.

Agenda

- Welcome.
- Objectives.
- VFC Overview.
- VFC Reminders and Expectations.
- VFC Products with Storage and Handling.
- Ordering vaccines in VOMS.
- Resources/VAERS Reporting.
- Pre-submitted questions.

Objectives

At the end of the webinar providers should be able to:

- Describe VFC eligibility requirements for patients.
- Understand the RSV and COVID-19 vaccines offered through the VFC Program, including proper storage and handling.
- Identify the process for ordering VFC RSV and COVID-19 vaccines utilizing VOMS.

VFC PROGRAM

VFC Eligibility

Children through 18 years of age who meet at least one of the following criteria are eligible to receive VFC vaccine:

- **Medicaid eligible:** A child who has health insurance covered by a state Medicaid program.
- **Uninsured:** A child who has no health insurance coverage.
- **American Indian or Alaska Native:** As defined by the Indian Health Care Improvement Act (25 U.S.C. 1603).
- **Underinsured:** Underinsured children are eligible to receive VFC vaccine **only** through a federally qualified health center (FQHC), rural health clinic (RHC), or a public health department that receives deputized authority from a FQHC or RHC.

For the purposes of VFC, **underinsured** includes:

- Children who have commercial (private) health insurance, but the coverage does not include vaccines;
- Children whose insurance covers only selected vaccines (VFC eligible for non-covered vaccines only); and
- Children whose insurance caps vaccine coverage at a certain amount (once that coverage amount is reached, these children are categorized as underinsured).

Temperature Monitoring

- Each VFC site is required to adhere to the following minimum standards for temperature monitoring:



MORNING

- Log current temperature
- Log Minimum and Maximum and clear history



EVENING (30 minutes before close)

- Log current temperature

Quarantine vaccine and call 1-800-282-0546 if:

1. Out-of-range minimum or maximum temperature.
2. Out-of-range current temperature.
3. Alarm indicating a temperature excursion occurred.

Private Supply Inventory Consideration

Participating providers are expected to ensure adequate vaccine supply for VFC and non-VFC eligible populations.

- VFC providers will be allowed a flexible, time-limited ramp-up period to meet the private inventory requirement for nirsevimab and COVID-19. During this time, ODH will not require VFC providers to meet the private inventory minimum requirements for these two vaccines if providers do not intend to vaccinate their private pay patients with RSV and COVID-19 vaccines.
- **VFC providers have until August 31, 2025, to meet the private inventory requirement.**

Borrowing Between Vaccine Supplies

If borrowing occurs:

- Ohio VFC providers must use the [VFC Borrowing Form](#) to document borrowed doses.
- Borrowed nirsevimab must be repaid within one month. Doses borrowed are to be replaced dose-for-dose and administered to the appropriate population (e.g., if VFC vaccine is borrowed for a privately insured patient and then repaid to VFC inventory, the repaid dose must be administered to a VFC-eligible child).
- If a provider borrows VFC doses for privately insured patients, they must maintain documented proof of privately purchased doses which includes the number of doses, lot numbers, and documentation that authenticates doses repaid were administered to the VFC eligible children.

RSV Vaccines

RSV Vaccine or Monoclonal Antibody For Infants

RSV usually causes mild symptoms but can cause severe illness in infants and some young children.


There are two safe and effective immunizations to prevent lower respiratory tract infection in infants.

1. A **maternal vaccination** (Pfizer's **ABRYSVO**) given to mom during pregnancy.
2. A **monoclonal antibody (Beyfortus)** given to the **baby** shortly after birth.

Either immunization is recommended, but administration of both, the maternal and the monoclonal, is not needed to protect most infants.

RSV Vaccine For Infants

The packaging for ABRYSVO and for Beyfortus is different and should help health care staff avoid confusion when using the correct product.



Maternal Vaccination: Abrysvo



Monoclonal Antibody: Beyfortus



Maternal Vaccination (Abrysvo)

Abrysvo: Infant Protection Through Maternal Vaccination

Pfizer's Abrysvo is **the only RSV vaccine approved for maternal vaccination** to prevent RSV in infants.

- Abrysvo for maternal vaccination is administered to pregnant women in their **gestational weeks 32 through 36 and six days**.
- **Do not** administer **after the 37th gestational week**.
- Infants born to mothers who received Abrysvo will **most likely not** require Beyfortus vaccination at birth.




Maternal Vaccination

Pregnant women are at a higher risk of developing lower respiratory tract issues from RSV infection. In most parts of the U.S., **RSV circulation is seasonal**, typically starting during the fall and peaking in the winter.

In Ohio, pregnant women between gestational weeks 32 – 36 and six days can be vaccinated with Abrysvo.

Beginning: **September first** (1st).

Ending: **Last day of January** (31st) the following year.



Maternal Vaccination

Abrysvo may be received during one pregnancy only.

- If the mother received Abrysvo during pregnancy and gave birth, then becomes pregnant again, the **following child or children will receive Beyfortus.**

All RSV vaccinations for adults are one-time (one dose) only.



Abrysvo Administration

Three presentations of ABRYSVO are available for intramuscular injection (0.5mL).

1. ABRYSVO Act-O-Vial is supplied in cartons of one and 10 Act-O-Vials, without syringes or needles. This is a double chambered vial with a stopper separating the lyophilized antigen from the sterile water diluent. A syringe with needle is required for administration. **Note: this product is not available through VFC in Ohio.**
2. ABRYSVO vial and prefilled syringe presentation is supplied in cartons of one, five, and 10 kits, without needles. Each kit includes a vial of Lyophilized Antigen Component, a prefilled syringe containing Sterile Water Diluent Component, and a vial adapter. **Note: this product is available through VFC in the 1 kit presentation in Ohio.**
3. ABRYSVO vial and vial presentation is supplied in cartons of five and 10 doses packaged without syringes or needles. Each carton includes vials of Lyophilized Antigen Component and vials of Sterile Water Diluent Component. **Note: this product is not available through VFC in Ohio.**




Please see [ABRYSVO's package insert](#) for specific instructions on reconstituting the vaccine for each type of presentation .

Abrysvo RSV Vaccine Presentation

Vial and prefilled syringe presentation - available for VFC.

- The vial and prefilled syringe presentation is supplied in cartons containing a kit(s). Each kit includes a vial of Lyophilized Antigen Component (a sterile white powder), a prefilled syringe containing Sterile Water Diluent Component, and a vial adapter.
- Needle for administration not included.


Reconstitution Instructions for Vial and Prefilled Syringe Presentation



Abrysvo Storage and Handling

Before reconstitution:

- Store vaccine and diluent refrigerated between 2°C and 8°C (36°F and 46°F).
- Store these components in their original package and keep them together in the refrigerator to optimize organization.
- **Never freeze the vaccine or diluent.**



[Image of vaccine refrigerators.](#)

Abrysvo Storage and Handling

After reconstitution:

- Immediately administer the vaccine; you should prepare the vaccine only when ready for use.
- If you **do not immediately administer** the vaccine, there are some minor differences in storage:
 - **Store the reconstituted vaccine ONLY at room temperature** [15°C to 30°C or (59°F to 86°F)] and use within four (4) hours.
 - **Do NOT refrigerate.**
 - This is very different than other reconstituted vaccines. For this vaccine, **DO NOT put it back in the refrigerator after reconstitution.**
 - **Never freeze** the vaccine or diluent.

Abrysvo Storage and Handling

Once you’ve reconstituted the vaccine, you **begin a four-hour beyond-use date clock**.

You must use the reconstituted vaccine **within four hours**.

- When the **four hours have passed**, the dose must be **wasted and disposed**.
- Do not administer expired vaccine.



Abrysvo RSV Vaccine Beyond Use Date		
Lot number		
Today's date		Time:
USE BY		
Date		Time:
After this date/time, do NOT use this vaccine. Dispose vaccine and syringe. Decrement inventory.		
Name		

Monoclonal Antibody For Infants (Beyfortus)

Monoclonal Antibody Products For Infants

There are two injectable monoclonal antibody products that help protect infants and young children from lower respiratory tract infection caused by RSV.

- Nirsevimab (Beyfortus).
- Palivizumab (Synagis).

This presentation will focus on Beyfortus as it is available through the VFC Program.

Beyfortus



- Beyfortus is an injectable monoclonal antibody that prevents severe RSV disease in infants and young children.
- Monoclonal antibodies do not activate the immune system, as would occur with infection or vaccination (also known as active immunization).
- Rather, the antibodies themselves protect against disease (i.e., passive immunization).

Beyfortus

- Beyfortus does not activate the immune system, so protection is likely most effective for several weeks after administration, and then protection wanes over time.
- Beyfortus does not provide long-term immunity to RSV disease but provides protection to infants when they are most at risk of getting severe RSV disease.
- As children get older, they are less likely to get severe symptoms from RSV infection.

Beyfortus

- Beyfortus is available in a 50 mg (0.5mL) and a 100 mg (1.0mL) single use, pre-filled syringe.
- Check the labels on the carton and pre-filled syringe to ensure the correct dosage of product is being used.



Storage of Beyfortus

Store refrigerated Beyfortus in the original carton between 36°F to 46°F (2°C to 8°C).

- May be kept at **room temperature** 68°F to 77°F (20°C to 25°C) for a **maximum of eight hours**.
- Beyfortus must be used **within eight hours once** removed from the refrigerator.
- Discard if not used within eight hours.
- Protect from light.




Beyfortus Storage Don'ts

- Do **NOT** freeze, shake or expose to heat.
- Do **NOT** inject Beyfortus if the liquid is cloudy, discolored, or it contains large particles or foreign particulate matter.
- Do **NOT** use if the Beyfortus pre-filled glass syringe has been dropped or damaged, the security seal on the carton has been broken, or the expiration date has passed.



Beyfortus 50mg (0.5mL)


- Beyfortus is available in a 50 mg (0.5mL) single use, pre-filled syringe. Check the labels on the Beyfortus carton and pre-filled syringe to ensure the correct dosage of product is being used.



- Infants less than 8 months, weighing **less than 5 kg (less than 11lbs)** should receive one 50mg dose.
- Concomitant administration is allowed with routine immunizations with no interference.

Beyfortus 100mg (1.0mL)

- Beyfortus 100 mg (1.0mL) is in a single use, pre-filled syringe. Check the labels on the Beyfortus carton and pre-filled syringe to ensure the correct dosage of product is being used.









- Infants less than 8 months, weighing **5 kg or more (greater than or equal to 11lbs)** receive one **100mg dose**.
- Children eight to 19 months of age who remain at increased risk for severe RSV disease in their **second RSV season**, should receive a **200 mg** dose **administered as two IM injections (2 x 100 mg)**.
- Concomitant administration is allowed with routine immunizations with no interference.

Beyfortus Administration Don'ts

The correct dose by weight must be used.

- You **cannot use** two 50mg doses if a 100mg dose is required.
- You **cannot use** half of a 100mg dose if 50mg dose is required.



Nirsevimab Clinical Considerations

The Advisory Committee on Immunization Practices (ACIP) recommends:

All infants aged less than 8 months born during or entering their first RSV season are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥5 kg).

Providers should target administration:

RSV Season One		
Births by Month	When to Administer	Dosage by Weight
October through March	• Administer during birth hospitalization.	50mg if < 5Kg or <11lbs 100mg if ≥ 5Kg or ≥11lbs
	• Administer within first week of life or first check up.	
	• Administer upon discharge from prolonged hospitalization.	
April through September	• Administer in October or anytime during RSV season.	
	• Infant must be less than 8 months of age.	


RSV First Season - One Dose For Infants

One dose of Beyfortus is recommended for infants younger than eight months of age who were born shortly before or are entering their first RSV season (typically fall through spring) if:

- The mother did not receive an Abrysvo vaccination during pregnancy.
- The mother's RSV vaccination status is unknown.
- The infant was born within 14 days of maternal RSV vaccination.

Beyfortus

- Beyfortus is given during the infants' **first RSV season** before they are eight months old.
- The dose is based upon their weight.
 - If the infant is **less than 5 kilograms**, they receive a **50mg/0.5mL/IM**.
 - If the infant weighs **5 kilograms or more**, they will receive **100mg/1.0mL/IM**.



RSV Season Two For Older Infants

- Beyfortus is recommended for some older infants aged **eight through 19 months** old **who are at increased risk** for severe RSV disease and entering their second RSV season.
- These older infants are recommended to receive Beyfortus shortly before or during their second RSV season.

RSV Season Two For Older Infants

Infants at increased risk include:

- American Indian/Alaska Native children.
- Children with chronic lung disease of prematurity who require medical support during the six months before the start of their second RSV season.
- Children with severe immunocompromise.
- Children with severe cystic fibrosis.

Children ages eight months and older **who are not at increased risk** of severe RSV disease **should not receive** Beyfortus for their second season.

RSV Season Two For Older Infants

- For **RSV Season Two** infants and young children eight months through 19 months of age, will receive a total dose of **200mg**.
- That is achieved by giving **two**, **100mg/1.0mL** doses (one dose in each leg).
- Regardless of body weight.


Second Season



Eight
through 19
months old
who are at
increased
risk

- 200 mg administered as **two IM injections** of **100mg/mL**.

Timing of Abrysvo and Beyfortus Administration



Except in rare circumstances, Beyfortus is not needed for most infants younger than age eight months who are born 14 or more days after their mother received an Abrysvo vaccination.

2024-2025 COVID-19 Vaccines


Moderna/Spikevax 2024-2025 COVID-19 Vaccine

Moderna has two presentations for their 2024-2025 COVID-19 vaccine.

- Spikevax for ages 12 years and older.
- Moderna for ages six months – 11 years.

Moderna/Spikevax

- Age: 12 years and older.
- NO diluent.
- Prefilled Syringes (PFS).
- Ten (10) doses per carton.
- PFS cartons contains five blisters; each blister contains two syringes.
- Each syringe is one dose of 50mcg/0.5mL.



2024-2025 Moderna/Spikevax			12 Years and Older
COVID-19 vaccination history	Number of doses indicated	Dosage (ug/mL)	Interval between doses
Unvaccinated.	One.	50 ug/0.5 mL	Dose One: NOW.
One or more doses of any COVID-19 vaccine not including 2024-2025 presentation.	One.	50 ug/0.5 mL	At least eight weeks after last COVID-19 vaccine dose.
People aged 65 years and older are to receive ONE dose of the 2024-2025 COVID-19 vaccine. They are NOT ELIGIBLE to receive an additional dose of the 2024-2025 COVID-19 vaccination if they are immune competent.			
Persons aged 12 years and older who are moderately or severely immunocompromised: Complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2024-2025 Formula).		Any further additional doses should be administered at least two months after the last COVID-19 vaccine dose.	

Moderna Vaccine (Six Months - 11 Years)

- Age: six (6) months through 11 years.
- Prefilled syringes.
- Single dose of 25mcg/0.25mL.
- No diluent.
- Ten (10) doses per carton.
- Each carton contains five blisters, each blister holds two prefilled syringes.

2024-2025 Moderna					Six Months Through 11 Years			
COVID-19 vaccination history		Number of doses indicated		Dosage (ug/mL)		Interval between doses		
Unvaccinated.		Two.		25 ug/0.25 mL		Dose One: NOW. Dose Two in four to eight weeks.		
	Six months-Four years.							
	Five years – 11 years.	One.		25 ug/ 0.25 mL		Dose One: NOW.		
One or more doses of COVID-19 vaccine; not including 2024-25 season.		One.		25 ug/0.25 mL		At least eight weeks after last COVID-19 vaccine dose.		
People aged six months through 11 years who are moderately or severely immunocompromised: Complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2024-2025 Formula).						Any further additional doses should be administered at least two months after the last COVID-19 vaccine dose.		

Moderna/Spikevax 2024-25 COVID-19 Vaccine Storage

Moderna and **Spikevax** vaccines may be stored frozen or refrigerated.

- PFSs may be kept in vaccine freezers until expiry.
 - Once vaccine has been moved to a refrigerator unit, the vaccine may be kept for a total of up to **60-days or expiry date** whichever is first.
 - Do NOT refreeze.
- Minimize exposure to room light and avoid exposure to direct sunlight and ultraviolet light. Thawed PFSs can be handled in room light conditions.
- Store vaccine in the carton.

2024-2025 COVID-19 Vaccine Storage

Moderna and Spikevax storage after thawing:

- PFSs may be stored refrigerated for up to 60 days prior to first use or up to the printed expiry date on the carton.
 - Single use. Gently swirl; **DO NOT SHAKE** the PFS.
- PFSs may be stored at room temperature **for up to 12 hours**.
 - (8°C to 25°C OR 46°F to 77°F).
- **Do not refreeze once thawed.**

Freezer Temperature

-50°C to -15°C
-58°F to 5°F

Refrigerator Temperature

2°C to 8°C
36°F to 46°F

Room Temperature

8°C to 25°C
46°F to 77°F

Moderna 2024-25 COVID-19 Vaccine Storage

Thawing times.

- PFSs may be thawed in a vaccine refrigerator.
 - Minimum time to thaw a PFS in a refrigerator (2°C to 8°C or 36°F to 46°F) is one hour with 15 minutes at room temperature prior to administration.
- PFSs may be stored at room temperature **for up to 12 hours.**
 - (8°C to 25°C OR 46°F to 77°F)
- **Do not refreeze once thawed.**

Presentation	Thaw in Refrigerator	Thaw at Room Temperature
PFS 50mcg/0.5mL	Thaw between 2°C to 8°C (36°F to 46°F) for one hour. Let PFS stand at room temperature for 15 minutes before administering.	Thaw between 8°C to 25°C (46°F to 77°F) for 45 minutes.

Pfizer-BioNTech/Comirnaty 2024-2025 COVID-19 Vaccine

Pfizer-BioNTech has three presentations for the 2024-2025 COVID-19 vaccine.

Comirnaty 12 years+.

Pfizer-BioNTech COVID-19 vaccine for children five through 11 years.

Pfizer-BioNTech COVID-19 vaccine for children six months through four years.

2024-2025 Pfizer-BioNTech / Comirnaty 12 years and older.

COVID-19 vaccination history	Number of doses indicated	Dosage (mL/ug)	Vaccine label colors	Interval between doses
Unvaccinated	One.	0.3 mL/30 ug	Gray	Dose One: NOW.
Two or more doses of COVID-19 vaccine Pfizer-BioNTech	One.	0.3 mL/30 ug	Gray	At least eight weeks after last COVID-19 vaccine dose.
People ages 12 years who are moderately or severely immunocompromised: Complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2024-2025 Formula).			Gray	Any further additional doses should be administered at least two months after the last COVID-19 vaccine dose.




2024-2025 Pfizer-BioNTech Five through 11 years.

COVID-19 vaccination history	Number of doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	One.	0.3 mL/10 ug	Blue	Dose One: NOW.
Two or more doses of COVID-19 vaccine Pfizer-BioNTech	One.	0.3 mL/10 ug	Blue	At least eight weeks after last COVID-19 vaccine dose
People ages five through 11 years who are moderately or severely immunocompromised: Complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2024-2025 Formula).			Blue	Any further additional doses should be administered at least two months after the last COVID-19 vaccine dose.

2024-2025 Pfizer-BioNTech Six-months through Four-years.				
COVID-19 vaccination history	Number of doses indicated	Dosage (mL/ug) After dilution 1.1mL NS/vial	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Three.	0.3 mL/3 ug	Yellow	Dose One: NOW. Dose Two: Three weeks after Dose One. Dose Three: At least eight weeks after Dose Two.
One prior dose of COVID-19 vaccine Pfizer-BioNTech	Two.	0.3 mL/3 ug	Yellow	Dose One: Minimum of three weeks after the most recent COVID-19 vaccine. Dose Two: At least eight weeks after Dose One.
Two or more doses of COVID-19 vaccine Pfizer-BioNTech	One.	0.3 mL/3 ug	Yellow	At least eight weeks after last COVID-19 vaccine dose.
People ages six months–four years who are moderately or severely immunocompromised: Complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. At least one dose should be with a COVID-19 vaccine (2024-2025 Formula).			Yellow	Any further additional doses should be administered at least two months after the last COVID-19 vaccine dose.

Pfizer-BioNTech/Comirnaty Storage & Handling

Pfizer-BioNTech/Comirnaty 2024-2025 COVID-19 Vaccine

Product by Age	Label Color Cap Color	Presentation	Diluent	Storage		
				ULT Freezer	Refrigerator	Freezer
Comirnaty 12 years +	Gray	Prefilled syringes (PFS)	NO	NO	YES Until Expiry	
Five through 11 years	Blue	Single Dose Vials	NO	YES →	YES Up to 10 weeks	
Six months through four years	Yellow	3-Dose Vial	YES 1.1mL Arrives in a separate shipment.	YES →	YES Up to 10 weeks (NOT punctured)	

Pfizer-BioNTech/Comirnaty (12 yrs+)

Storage & Handling

- If cartons of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) are received at 2°C to 8°C (35°F to 46°F), they should be stored at 2°C to 8°C (35°F to 46°F).
 - Store in the refrigerator through the expiration date printed on the prefilled syringe and cartons.
 - **DO NOT FREEZE.**
 - May be stored at room temperature [8°C to 25°C (46°F to 77°F)] for a **total of 12 hours prior to the application of a needle onto a PFS.**

Pfizer-BioNTech Pediatric COVID-19 (5 -11 yrs)

Storage & Handling

- Frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F) until the expiration date printed on the vials and cartons.
- May take up to two hours to thaw in refrigerator.
- Once placed in the refrigerator, there is a **10-week expiry date from the date it is placed in the refrigerator.** This should not exceed the expiration date printed on the vial and cartons.
- May be stored at room temperature [8°C to 25°C (46°F to 77°F)] for a **total of 12 hours prior to the first puncture.**

Pfizer-BioNTech Pediatric COVID-19 (6 months- 4 yrs)

Storage & Handling

- Frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F) until the expiration date printed on the vials and cartons.
- Once placed in the refrigerator, there is a **10-week expiry date from the date it is placed in the refrigerator**. This should not exceed the expiration date printed on the vial and cartons.
- Multiple dose vials take 30 minutes to thaw at room temperature [up to 25°C (77°F)]. May take up to two (2) hours to thaw in refrigerator.
- May be stored at room temperature [8°C to 25°C (46°F to 77°F)] for a **total of 12 hours prior to the first puncture**.
- Multiple dose vials require normal saline diluent. Diluent is shipped separately from the vaccine.
- After dilution, multiple dose vials should be stored between 2°C to 25°C (35°F to 77°F) for **up to 12 hours**. Multiple dose vials should be discarded 12 hours after dilution.

Novavax 2024-2025 COVID-19 Adjuvanted Vaccine

Novavax 2024-2025 COVID-19 Vaccine 12 years+

Novavax 2024-2025 COVID-19 Vaccine

The Novavax 2024-2025 COVID-19 vaccine is a protein subunit vaccine. It is a two-dose series (0.5 mL intramuscularly), three weeks between doses.


- Approved for ages 12 years and older.
- Shipped refrigerated.
- Supplied in PFS.
- No diluent.
- Store in refrigerator.



Novavax 2024-2025 COVID-19 Vaccine

Novavax 2024-2025 COVID-19 Vaccine, Adjuvanted	
Storage	Length of Time
Unopened, refrigerated vaccine in PFS.	Three months.
Refrigerated PFS with needle attached.	PFS must be used immediately or discarded if not used immediately.
Room temperature PFS with needle attached.	PFS must be used immediately or discarded if not used immediately.

Ordering RSV and COVID-19 Vaccines



- The Vaccine Ordering Management System (VOMS) is available 24 hours a day, seven days a week to accept provider orders for VFC vaccine.
- Generally, providers should anticipate seven to 10 days from the date a vaccine order is entered into VOMS, and when the vaccine is delivered to your facility.

Ordering Beyfortus

Product	Weight Indication	Presentation	Min Order Quantity
Beyfortus 50mg (0.5mL)	Under 11 pounds	Single dose vial; 5 pack	5
Beyfortus 100mg (1.0mL)	11 pounds and over	Single dose vial; 5 pack	5

- These products are available in the **VFC-RSV** order set.
- Due to the limitations of Ohio's allocation, there will be order caps.
 - The Immunization Program is utilizing Provider Profile data to determine provider order caps.
 - Contact the Program at 1-800-282-0546 if your location has concerns about your order.

Beyfortus Ordering Considerations

- Some requests for RSV vaccine may be reduced due to:
 - Limitations of Ohio's biweekly allocation (i.e., product supply at the McKesson Distribution Center).
 - Inconsistency with Provider Profile data.
 - Ensuring equity across our providers.
- Providers can place frequent off-cycle orders **as needed**.
- A provider's utilization history and on-hand inventory will be considered when evaluating off-cycle orders for approval.
- ODH Immunization Program will process orders as vaccine supply is available.

Beyfortus Ordering Considerations

- Ohio will receive limited biweekly nirsevimab thresholds of both presentations, 50mg and 100mg, from the CDC.
- Ohio's initial biweekly thresholds from the CDC are higher for 100mg product than the 50mg product.
- Providers should account for infants born April through September when nirsevimab is not recommended for administration, a majority of whom will weigh more than the 11 lb (5kg) cut off when they return to their provider after October 1 for a well check. These infants will be eligible to receive the 100mg product.

Ordering Abrysvo

Product	Presentation	Min Order Quantity
Abrysvo	Prefilled syringe kit	1

- This product is available in the **VFC-Abrysvo** order set.
- Providers are not required to maintain an inventory of VFC Abrysvo, but they are encouraged to order it if the target population is served at their location.

2024-2025 VFC COVID-19 Vaccines

Product	Age Indication	Presentation	Min Order Quantity	Shipment Temperature
COVID-19 Pfizer Comirnaty	12+ years	Single dose glass syringe; 10 pack	10	Refrigerated
COVID-19 Pfizer	5 – 11 yrs.	Single dose vial; 10 pack	10	Ultra Cold
COVID-19 Pfizer	6 mos. – 4 yrs.	3-dose multi-dose vial, 10 pack	30	Ultra Cold
COVID-19 Moderna Spikevax	12+ years	Single dose syringe; 10 pack	10	Frozen
COVID-19 Moderna	6 mos. – 11 yrs.	Single dose syringe; 10 pack	10	Frozen
COVID-19 Novavax*	12+ years	Single dose syringe; 10 pack	10	Refrigerated

* Novavax is not currently available for order. Please contact the Immunization Program if you have a client who is not eligible to receive other COVID-19 vaccine presentations.

Ordering 2024-2025 COVID-19 Vaccines

These products are available in these VOMS order sets.

- COVID-19 VACCINE - VFC Moderna-Novavax.
- COVID-19 VACCINE - VFC Pfizer.

RSV Vaccine Resources

Nirsevimab:

- [Beyfortus.pdf \(sanofi.us\).](#)
- [ACIP Evidence to Recommendations for Use of Nirsevimab in Infants born during the RSV season or entering their first RSV season | CDC.](#)
- [Healthcare Providers: RSV Immunization for Children 19 Months and Younger | CDC.](#)
- [Immunization Information Statement: Nirsevimab.](#)

COVID-19 Vaccine:

- [CDC COVID-19 Interim Clinical Considerations.](#)
- [COVID-19 Standing Orders and BUD labels](#)

Vaccine Adverse Event Reporting System (VAERS) and MedWatch

VAERS reporting assistance:

- Email info@VAERS.org.
- or
- Call 1-800-822-7967.

MedWatch:

- [FAQ for MedWatch Reporting.](#)

Contact Us

Phone

(614) 466-4643
1-800-282-0546

Email

vfc@odh.ohio.gov
Immunize@odh.ohio.gov
Impact@odh.ohio.gov

Webpage Resources

[VFC Providers](#)

[ImpactSIIS Job Aids and Videos](#)

QUESTIONS?

ODH.OHIO.GOV



Department of
Health



**Department of
Health**